Q-omics provides the consensus-scored MRPS18A profile across patient tissues and cancer cell-line models. MRPS18A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPS18A is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, MRPS18A protein abundance shows 20,683 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where MRPS18A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS18A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS18A survival associations across molecular data types. MRPS18A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS18A RNA expression–survival associations across cancer types. High MRPS18A expression shows unfavorable associations in LAML, LIHC, PAAD and ACC, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPS18A RNA expression.
This table summarizes MRPS18A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS18A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS18A shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, LUAD, LUSC and CHOL. The KICH box plot shows higher MRPS18A RNA expression in normal versus tumor tissue (log2 FC = −1.131, t-test p < 0.001).
This table shows molecular features associated with MRPS18A in patient tissues and cancer cell lines. In patient samples, MRPS18A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS18A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
